CASI Pharmaceuticals Inc CASI

NAS: CASI | ISIN: US14757U2087   30/04/2025
1,940 USD (-2,76%)
(-2,76%)   30/04/2025

4 september 2024 · Casi Pharmaceuticals To Participate In The 2024 H.c. Wainwright Global Investment Conference · Persbericht

16 augustus 2024 · Casi Pharmaceuticals Announces Second Quarter 2024 Business And Financial Results · Persbericht

19 juli 2024 · Casi Pharmaceuticals Reports Development Relating To Its Disputes With Juventas · Persbericht

8 juli 2024 · CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP · Persbericht

26 juni 2024 · CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company · Persbericht

26 juni 2024 · CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He · Persbericht

15 mei 2024 · CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) · Persbericht

14 mei 2024 · Casi Pharmaceuticals Announces First Quarter 2024 Business And Financial Results · Persbericht

8 april 2024 · Casi Pharmaceuticals Reports Development Relating To Its Disputes With Juventas · Persbericht

28 maart 2024 · Casi Pharmaceuticals Announces Fourth Quarter And Full-Year 2023 Business And Financial Results · Persbericht

5 maart 2024 · CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China · Persbericht

16 februari 2024 · Casi Pharmaceuticals Announces First Dosing Of Folotyn® In China · Persbericht

8 november 2023 · Casi Pharmaceuticals Announces Market Approval Of Cnct19 By China Nmpa · Persbericht

2 november 2023 · Thinking about buying stock in NXU, AERWINS Technologies, Chevron, CASI Pharmaceuticals, or Aldeyra Therapeutics? · Persbericht

11 augustus 2023 · Casi Pharmaceuticals Announces Second Quarter 2023 Business And Financial Updates · Persbericht

1 augustus 2023 · Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals · Persbericht

20 juli 2023 · CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 · Persbericht

17 mei 2023 · Casi Pharmaceuticals Announces First Quarter 2023 Financial Results · Persbericht

26 april 2023 · CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 · Persbericht

26 april 2023 · Casi Pharmaceuticals Announces Fourth Quarter And Full-Year 2022 Financial Results · Persbericht

Mijn selecties